ECG Telemetry Devices Market By Product Type (Hospital ECG Telemetry Systems, Mobile Cardiac Telemetry Systems, Wearable ECG Patches, Holter Monitors, Event Monitors, Portable Multi-Lead ECG Devices); By Component (ECG Sensors and Electrodes, Transmitters and Connectivity Modules, Monitoring Software, Cloud Platforms, Data Analytics and AI Algorithms, Central Monitoring Systems); By End User (Hospitals, Diagnostic Centers, Home Healthcare Providers, Telemedicine Platforms, Specialty Cardiology Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

ECG Telemetry Devices Market Advances with Wearable Monitoring, AI Analysis, and Multi-Lead Remote ECG Systems

The Global ECG Telemetry Devices Market will reach USD 2.3 billion by 2032, up from USD 1.2 billion in 2025, with a CAGR of 10.2%.

The ECG Telemetry Devices Market is moving away from conventional bedside and wired monitoring toward portable, wearable, and remotely connected cardiac monitoring systems. These devices capture the heart’s electrical activity and transmit ECG data to clinicians or monitoring centers, allowing continuous surveillance while patients remain mobile.

Hospitals use inpatient telemetry systems to monitor patients through chest electrodes connected to portable transmitters and central monitoring stations. Mobile cardiac telemetry (MCOT) and wearable ECG patches extend cardiac monitoring into home and outpatient settings, while Holter and event monitors remain widely used for longer-duration rhythm recording and symptom-based assessment.

Modern ECG telemetry systems rely on electrodes or wearable sensors, ECG acquisition hardware, wireless transmitters, cloud platforms, central monitoring stations, and automated alert software. Cellular, Bluetooth, Wi-Fi, and radio-frequency connectivity allow ECG information to move quickly between patients, monitoring centers, and healthcare professionals.

A major development is the rise of extended-wear, cable-free ECG patches. iRhythm Technologies’ Zio AT supports ambulatory cardiac telemetry with wireless transmission and AI-assisted ECG analysis. SmartCardia’s 7L ECG Patch provides seven-lead monitoring in a waterproof, cable-free form and supports continuous outpatient telemetry for up to 14 days with cloud-based alerts.

HeartBeam is advancing compact multi-lead monitoring through its AIMIGo and 3D ECG technology. Its credit-card-sized device captures three-dimensional cardiac signals and uses software to create a synthesized 12-lead ECG, supporting remote arrhythmia assessment without a conventional wired 12-lead setup.

Personal ECG monitoring is also gaining traction. AliveCor’s KardiaMobile 6L provides a portable six-lead medical-grade ECG and supports the detection of atrial fibrillation, bradycardia, and tachycardia. The product combines patient-operated hardware with AI-supported rhythm interpretation.

Artificial intelligence is becoming increasingly important as long-duration monitoring creates large volumes of ECG data. AccurKardia’s AccurECG 2.0 focuses on automated ECG interpretation across different compatible devices, while iRhythm uses AI-assisted analysis to identify and prioritize clinically relevant cardiac events.

AI is also being applied to implantable loop recorder monitoring. Implicity’s ILR ECG Analyzer processes remotely transmitted recordings from compatible implanted monitors and helps reduce false-positive events, making clinical review more efficient.

Hospital telemetry continues to advance alongside outpatient technologies. Norav Medical develops wireless ECG telemetry and rehabilitation monitoring systems that support patient mobility, multi-patient surveillance, and multi-lead ECG acquisition in clinical settings.

Key companies and products shaping the market are iRhythm Technologies with Zio AT, SmartCardia with the 7L ECG Patch, HeartBeam with AIMIGo and synthesized 12-lead ECG technology, AliveCor with KardiaMobile 6L, AccurKardia with AccurECG 2.0, Implicity with the ILR ECG Analyzer, and Norav Medical with wireless hospital and rehabilitation telemetry systems.

Overall, growth in the ECG Telemetry Devices Market is being driven by wearable patches, longer monitoring periods, real-time wireless connectivity, cable-free multi-lead ECG, AI-powered interpretation, cloud-based monitoring, and remote cardiac diagnostics. These advances are helping move cardiac surveillance beyond hospitals and into outpatient and home-care environments.

 

What Is Driving Growth in the ECG Telemetry Devices Market?

The strongest demand driver is the growing number of patients who require continuous or extended cardiac rhythm surveillance. A 2024 JACC analysis estimated that at least 10.55 million U.S. adults had diagnosed atrial fibrillation at the end of 2019, representing 4.48% of U.S. adults. Globally, approximately 52.55 million AF/AFL cases were prevalent in 2021, with around 4.48 million new cases recorded during that year.

Atrial fibrillation is commercially important because rhythm abnormalities may occur intermittently and may not be captured during a short clinical ECG. Hospitals use telemetry for patients requiring continuous observation, while ambulatory monitoring allows physicians to assess cardiac activity over longer periods after patients leave a hospital or clinic.

The addressable clinical base also extends beyond atrial fibrillation. Approximately 20.5 million U.S. adults have coronary heart disease, around 805,000 heart attacks occur annually, and nearly 6.7 million U.S. adults have heart failure. Global estimates identify approximately 254.3 million ischemic heart disease cases and 56.5 million heart-failure cases in 2021. Acute myocardial infarction, cardiac procedures, decompensated heart failure, and concurrent arrhythmias create particularly strong requirements for cardiac surveillance.

Cardiovascular mortality further supports investment in monitoring capacity. Atrial fibrillation was mentioned on 232,030 U.S. death certificates in 2021, including 28,037 deaths where AF was the underlying cause. Heart failure was mentioned on 452,573 U.S. death certificates in 2023. Hospitals and cardiology practices therefore have a continuing need to identify clinically relevant rhythm changes among high-risk patients.

 

Which Product Types Are Shaping ECG Telemetry Device Revenue?

Wireless ECG devices are gaining importance as hospitals expand cardiac monitoring beyond fixed bedside locations. They allow ECG data to be transmitted to centralized monitoring environments while patients move within designated hospital areas.

This supports telemetry expansion across cardiac wards, emergency departments, step-down units, recovery areas, and other settings where continuous observation is required without keeping every patient connected to a bedside monitor.

Hospital purchasing is consequently becoming more infrastructure-oriented. GE HealthCare states that an ApexPro CH configuration can monitor up to 438 patients across its coverage area, while Mindray describes network configurations supporting up to 1,200 telemetry devices. These capacities illustrate how purchasing decisions increasingly involve network scale, centralized monitoring, wireless coverage, and compatibility with broader patient-monitoring systems.

Wireless ECG revenue is also supported by replacement cycles, additional transmitters, software upgrades, and expansion of telemetry-enabled hospital areas. Suppliers with an existing monitoring-system footprint can benefit when hospitals expand capacity without replacing their entire monitoring ecosystem.

Wearable ECG devices are benefiting from the shift toward longer-duration outpatient cardiac monitoring. Their commercial value is strongest where physicians need cardiac information beyond a short office visit or hospital stay.

The segment increasingly operates through a combination of wearable hardware, connectivity, analysis software, technician review, patient support, and physician reports. This creates recurring revenue each time a new patient begins a monitoring episode.

Commercial utilization is already significant. Philips reported that BioTelemetry's ambulatory cardiac-monitoring network historically served more than one million patients annually, across several ambulatory monitoring modalities. iRhythm reported more than 12 million cumulative patient reports across its ambulatory cardiac-monitoring services through 2025.

Wearable monitoring is therefore shifting competitive emphasis toward physician referrals, payer access, monitoring-center capacity, patient adherence, and report delivery. Suppliers able to manage the entire monitoring episode can capture more value than companies competing only through the physical wearable.

Holter monitors remain an established ambulatory ECG category and continue to serve patients requiring continuous rhythm recording over defined monitoring periods. Their widespread clinical familiarity supports continued use across cardiology practices and diagnostic centers.

Competition is changing as conventional Holter monitoring becomes connected with digital reporting, cloud-based data management, and longer-duration wearable ECG services. Providers increasingly maintain several ambulatory monitoring options so physicians can select monitoring duration according to the patient's symptoms and suspected rhythm abnormality.

Companies offering Holter monitoring alongside extended ECG and mobile cardiac telemetry can therefore serve a wider referral base while sharing software, reporting, and clinical-service infrastructure across multiple monitoring formats.

 

Which End Users Generate the Most Relevant ECG Telemetry Demand?

Hospitals remain a core ECG telemetry customer because continuous cardiac surveillance is required across multiple inpatient pathways. Demand comes from cardiac wards, emergency care, step-down units, selected heart-failure admissions, post-procedural monitoring, and patients at risk of arrhythmia or ischemic changes.

Hospital revenue is driven by more than the number of transmitters purchased. Health systems invest in central monitoring stations, networking, wireless infrastructure, software, replacement equipment, maintenance, and expansion of monitored capacity.

GE HealthCare, Mindray, Nihon Kohden, Philips, and Spacelabs Healthcare participate in this hospital-oriented market. Their competitive positions depend heavily on integration with existing monitoring environments, centralized visibility, workflow reliability, and the ability to support large numbers of monitored patients.

Diagnostic centers benefit from rising referrals for longer cardiac rhythm assessment outside hospitals. Patients with intermittent palpitations, dizziness, syncope, or suspected arrhythmias may require extended monitoring when shorter ECG examinations do not capture an event. CMS specifically recognizes such symptoms among circumstances that may support extended ECG monitoring when clinically appropriate.

The commercial opportunity increasingly includes Holter monitoring, wearable ECG devices, mobile cardiac telemetry, digital interpretation, and report delivery. Diagnostic providers capable of supporting several monitoring durations can capture a broader range of physician referrals.

Home healthcare is becoming more commercially relevant as cardiac monitoring shifts from inpatient observation toward remote surveillance. Wearable devices can collect ECG information while selected patients continue their normal activities outside a hospital.

CMS recognizes mobile cardiovascular telemetry services lasting up to 30 consecutive days, with the technical service covering equipment, ECG transmission, analysis, reports, supplies, and technical support. This reimbursement model supports monitoring as a recurring healthcare service rather than a simple wearable-device transaction.

Home monitoring also generates demand for device logistics, replacement patient-contact components, connectivity, patient assistance, monitoring-center operations, and reporting. Companies capable of coordinating these services can capture a larger portion of each monitoring episode.

Telemedicine providers create an additional route for ECG telemetry by connecting remotely collected cardiac information with virtual clinical workflows. Wearable ECG and cloud-based monitoring platforms can provide physicians with objective cardiac data between face-to-face appointments.

The strongest opportunity lies in cooperation between telemedicine networks, cardiologists, diagnostic providers, and remote monitoring centers. ECG telemetry can extend a virtual consultation into a longer period of physiological observation, increasing the clinical value of remote cardiac care.

As this model develops, telemedicine platforms may also become important distribution and care-coordination partners for ECG monitoring suppliers, increasing the importance of software interoperability, patient engagement, secure data transfer, and payer access.

 

Why Is Mobile Cardiac Telemetry Creating Recurring Revenue?

Mobile cardiac telemetry creates recurring revenue because reimbursement is linked to monitoring episodes and associated services rather than only to hardware. CMS recognizes CPT codes 93228 and 93229, with one unit covering a monitoring course lasting up to 30 consecutive days.

The service model can include equipment, transmission, rhythm analysis, technician review, reporting, consumables, and technical support. Each additional patient entering ambulatory monitoring can therefore create another revenue-generating episode.

Payer relationships can materially expand this opportunity. Philips' 2025 agreement with Optum made its MCOT and ePatch services available to approximately 3.4 million covered policyholders, extending access to its ambulatory monitoring services.

iRhythm reported USD 747.1 million in 2025 revenue, with growth primarily associated with increased Zio service volume. Its disclosures also indicated increasing contribution from Zio AT, reflecting greater use of ambulatory services that provide more timely cardiac-event transmission.

 

How Does ECG Telemetry Fit Into Cardiac Treatment and Procedures?

ECG telemetry supports treatment decisions but is primarily a monitoring product rather than a therapeutic intervention. Rhythm information can influence medication management, additional diagnostic evaluation, cardioversion, catheter ablation, and follow-up after treatment.

A U.S. study of 4,834,977 adults with nontransient atrial fibrillation between 2019 and 2023 found that 70.40% received anticoagulant therapy, 80.64% received rate-control medication, and 31.02% received rhythm-control medication. The broad use of medical management keeps rhythm monitoring relevant across diagnosis, treatment adjustment, and follow-up.

Procedural pathways create additional concentrated demand. The Society of Thoracic Surgeons National Database contains information on nearly 10 million procedures and captures approximately 95% of U.S. adult cardiac surgery procedures, demonstrating the scale of the hospital procedural ecosystem in which peri- and post-procedural cardiac monitoring operates.

 

How Are Cloud Platforms Changing ECG Telemetry Competition?

Cloud-based analysis is moving ECG telemetry competition from hardware toward complete monitoring workflows. Connected systems increasingly combine ECG acquisition, data transmission, automated rhythm analysis, professional review, and clinician reporting.

The shift improves the commercial value of software and monitoring services because larger ECG datasets can be prioritized before human review. Suppliers can therefore scale patient volumes through analytics and centralized monitoring operations rather than increasing staff at the same rate as monitoring volume.

Hospital-focused companies such as GE HealthCare, Mindray, Nihon Kohden, and Spacelabs Healthcare compete largely through centralized patient-monitoring infrastructure. Philips, Boston Scientific, and iRhythm have greater exposure to ambulatory monitoring services, physician referrals, wearable ECG, and payer relationships.

Reliability is also becoming a stronger purchasing factor because remote monitoring depends on the full chain from ECG acquisition and transmission to software processing, technician review, and clinician notification. Hospitals and ambulatory providers therefore increasingly evaluate service operations and software quality alongside the device itself.

 

Which Regions Are Important in the ECG Telemetry Devices Market?

North America has a strong commercial position in ECG telemetry because of its large cardiovascular patient population, established hospital monitoring infrastructure, ambulatory reimbursement, and mature remote cardiac-monitoring networks. The United States has at least 10.55 million diagnosed AF patients, nearly 6.7 million adults with heart failure, and approximately 805,000 heart attacks annually. The presence of GE HealthCare, Boston Scientific, Philips' BioTelemetry operations, and iRhythm also supports a mature competitive environment across hospital and ambulatory monitoring.

Europe represents an established market for both hospital telemetry and ambulatory cardiac monitoring. Demand is linked to developed cardiovascular-care systems, ageing patient populations, hospital digitalization, and increasing use of connected monitoring outside traditional inpatient settings. The region also has an established supplier base, including Philips, alongside global patient-monitoring manufacturers serving European hospitals.

Asia-Pacific offers expanding ECG telemetry opportunities as hospital capacity, cardiology services, and connected-care infrastructure develop across major healthcare markets. Regional suppliers including Mindray and Nihon Kohden have established hospital patient-monitoring portfolios, positioning them to participate as healthcare systems increase centralized and wireless monitoring capacity.

Latin America, Middle East and Africa

Demand across Latin America, the Middle East, and Africa is concentrated in major hospitals, cardiac centers, and private healthcare networks. Expansion of specialist cardiovascular services and modernization of hospital monitoring infrastructure provide additional opportunities for ECG telemetry suppliers.

 

Who Are the Key Companies in the ECG Telemetry Devices Market?

The competitive landscape includes Philips, GE HealthCare, Boston Scientific, iRhythm Technologies, Mindray, Nihon Kohden, and Spacelabs Healthcare. Their positions vary significantly by care setting.

Philips – Global Leader in Integrated ECG Telemetry and Ambulatory Cardiac Monitoring Ecosystems is a diversified global healthcare technology company with a strong presence in both hospital patient monitoring and ambulatory cardiac diagnostics. In ECG telemetry, Philips provides centralized hospital monitoring systems as well as ambulatory cardiac monitoring services such as MCOT and wearable patch-based solutions. Its strength lies in integrating hardware, software, and service-based monitoring ecosystems across inpatient and outpatient care.

GE HealthCare – Advanced Hospital-Grade ECG Telemetry and Centralized Patient Monitoring Infrastructure Provider is a leading provider of hospital-based patient monitoring systems, including ECG telemetry platforms used in critical care, emergency departments, and cardiac units. The company focuses on large-scale hospital infrastructure, offering centralized monitoring stations, wireless telemetry networks, and integrated clinical data systems that support high-acuity patient management.

Boston Scientific – Cardiovascular Innovation Leader Supporting Rhythm Management and Diagnostic ECG Telemetry Pathways is primarily a cardiovascular device company with a strong focus on interventional cardiology and rhythm management. In the ECG telemetry space, its exposure is more indirect and centered on cardiac rhythm management solutions and diagnostic support technologies that complement long-term monitoring and arrhythmia detection pathways.

iRhythm Technologies – Digital Health Pioneer in Wearable ECG Patch Monitoring and Cloud-Based Cardiac Analytics is a specialized digital health company focused on ambulatory cardiac monitoring. Its flagship Zio service provides long-duration wearable ECG patch monitoring combined with cloud-based analysis and physician reporting. The company operates on a service-based model, generating recurring revenue through each patient monitoring episode rather than traditional device sales.

Mindray – High-Growth Global Supplier of Scalable Hospital ECG Telemetry and Patient Monitoring Systems is a global medical device manufacturer with a strong footprint in hospital patient monitoring systems, particularly in emerging and mid-tier markets. Its ECG telemetry solutions are widely used in centralized hospital monitoring environments, where scalability, cost efficiency, and integration with broader patient monitoring platforms are key competitive advantages.

Nihon Kohden – Precision-Focused ECG Telemetry Specialist for Critical Care and Cardiac Monitoring Excellence is a Japan-based medical technology company specializing in patient monitoring, diagnostic cardiology, and neurodiagnostic systems. In ECG telemetry, it provides hospital-grade monitoring solutions with a focus on reliability, waveform accuracy, and integration into intensive care and cardiac care workflows.

Spacelabs Healthcare – Established Leader in Wireless Hospital ECG Telemetry and Scalable Central Monitoring Systems is a dedicated patient monitoring company with a long-standing presence in hospital telemetry systems. It offers ECG monitoring solutions designed for critical care and cardiac units, emphasizing wireless telemetry, central monitoring systems, and scalable hospital-wide deployment.

Hospital-focused competition centers on centralized monitoring, wireless coverage, integration, installed infrastructure, and capacity expansion. Ambulatory competition depends more heavily on wearable devices, monitoring-center services, software, physician relationships, payer access, and report delivery.

Philips combines hospital monitoring with MCOT and ambulatory cardiac-monitoring services. GE HealthCare, Mindray, Nihon Kohden, and Spacelabs maintain established hospital telemetry offerings, while Boston Scientific and iRhythm have significant exposure to ambulatory cardiac monitoring. This mix of hardware and recurring services is gradually changing the revenue profile of the market.

 

What Is the ECG Telemetry Devices Market Outlook Through 2032?

The ECG Telemetry Devices Market is moving toward connected, wearable, and service-based cardiac monitoring. Hospital revenue will continue to come from telemetry capacity expansion, replacement equipment, networking, software, and system upgrades, while outpatient growth will increasingly depend on patient monitoring episodes, wearable ECG devices, remote analysis, and reporting services.

The strongest commercial opportunities are linked to the growing arrhythmia patient pool, sustained cardiovascular hospitalization, extended ambulatory monitoring, reimbursement-supported MCT services, larger centralized hospital networks, and cloud-based ECG analysis. Companies that combine reliable cardiac data acquisition with scalable monitoring operations, physician access, hospital integration, and payer relationships are positioned to capture a larger share of future revenue.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.2 Billion
Revenue Forecast in 2032	USD 2.3 Billion
Overall Growth Rate	CAGR of 10.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Component, By End User, By Geography
By Product Type	Hospital ECG Telemetry Systems, Mobile Cardiac Telemetry (MCOT) Systems, Wearable ECG Patches, Holter Monitors, Event Monitors, Portable Multi-Lead ECG Devices
By Component	ECG Sensors and Electrodes, Transmitters and Connectivity Modules, Monitoring Software, Cloud Platforms, Data Analytics and AI Algorithms, Central Monitoring Systems
By End User	Hospitals, Diagnostic Centers, Home Healthcare Providers, Telemedicine Platforms, Specialty Cardiology Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of cardiac rhythm disorders and demand for continuous monitoring Growing adoption of wearable ECG patches, remote patient monitoring, and cloud-based cardiac analytics Increasing integration of AI-powered ECG interpretation and wireless hospital telemetry infrastructure
Customization Option	Available upon request